Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2016-02-29 M&A Activity
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
M&A Activity Classification · 1% confidence The document is a press release dated February 29, 2016, announcing that Onxeo has reached an agreement to acquire DNA Therapeutics. It details the terms of the acquisition, including upfront payments, milestones, and royalty payments, and also provides an update on the development plan for Validive®. This content describes a significant corporate transaction (M&A) and financing/capital structure implications (share issuance for acquisition). Since the primary focus is the acquisition of another company, the most fitting category is M&A Activity (TAR). It is not a standard regulatory report (10-K, IR, ER) but a corporate announcement detailing a transaction.
2016-02-29 English
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is titled "Onxeo Reports 2015 Full-Year Results and Provides Business Update" and contains a detailed table of "Consolidated accounts (IFRS-compliant)" for the year ended 31/12/2015, comparing them to 2014. It explicitly discusses revenues, operating expenses, R&D spend, and net profit/loss for the full year. This content structure is characteristic of a comprehensive annual financial disclosure. Although it is presented as a press release announcing the results, the inclusion of the full, detailed, comparative financial tables makes it function as the primary disclosure of the annual financial performance, aligning best with the Annual Report (10-K) category, or potentially an Earnings Release (ER) if it were only highlights. Given the depth of the financial tables and the full-year scope, it is classified as the core financial reporting document, which maps to the 10-K definition (Official yearly report covering company activity and full financial performance), even if the format is a press release announcing the 10-K filing. The document length (12,635 chars) is substantial, suggesting more than just a brief release. FY 2015
2016-02-26 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is titled "Résultats de l'exercice 2015 et point sur l'activité" (2015 Fiscal Year Results and Activity Update) and explicitly states: "Onxeo S.A. [...] annonce aujourd'hui ses résultats consolidés pour 2015, et fait un point sur les événements marquants de 2015 et attendus en 2016." It contains detailed consolidated financial statements (Comptes consolidés 2015) comparing 2015 to 2014, including revenue, operating expenses, and net result, all under IFRS standards. This content structure—a comprehensive review of the full fiscal year's performance, including audited-like financial tables and management commentary—is characteristic of an Annual Report, although it is presented as a press release announcing the results. Since the document contains the full financial details for the year and is not merely a short announcement pointing to an attached report (the document length is substantial at 14,942 chars), it is classified as the Annual Report (10-K equivalent for non-US filers, or the underlying content of one). If a specific 10-K code were not available, 'AR' (Audit Report/Information) might be considered, but given the comprehensive nature covering the entire fiscal year's performance and financials, 10-K is the most appropriate fit for a full annual financial disclosure. FY 2015
2016-02-26 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 22, 2016, announcing a new collaboration between Onxeo and research centers to advance its oncology drug pipeline. It details preclinical research plans, mentions positive preliminary results, and includes forward-looking statements and contact information typical of corporate news releases. This type of announcement, which communicates significant business developments (like partnerships and research progress) but is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA), fits best under the general category for corporate news announcements. Since it is not a specific report (like AR, IR, or IP) but a general update on corporate activity and strategy, the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially Investor Presentation (IP) if it were structured as a presentation, but given the format, RNS serves as the best fit for a general corporate press release announcing strategic progress.
2016-02-22 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release issued by Onxeo S.A. announcing a new research collaboration with CIMA and the University of Navarra. It describes business development activities, specifically the expansion of clinical research programs for oncology assets. It does not contain financial statements, audit results, or regulatory filings, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news. FY 2016
2016-02-22 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a press release dated February 17, 2016, announcing that Onxeo management will present updates at upcoming investor conferences and medical meetings, and it also lists dates for future financial updates (Full-Year 2015 Results, Analyst Conference Call). This content is characteristic of an announcement intended to inform investors about future corporate activities, presentations, and upcoming report releases, rather than being the report itself (like a 10-K or IR). Since it is an announcement about corporate events and future financial reporting schedules, it fits best under the general category of investor relations communication. Given the options, it is not a specific report type (like ER, IR, 10-K) or a specific event outcome (like DVA, DIV). It is a general update aimed at investors regarding participation in external events and scheduling of internal updates. This type of general corporate update, which doesn't fit the highly specific categories like Director's Dealing (DIRS) or Capital Change (CAP), often falls under Regulatory Filings (RNS) as a catch-all for press releases not covered elsewhere, or potentially Investor Presentation (IP) if it were the presentation itself. However, since it is an announcement *about* attending conferences and *scheduling* calls, it is a general corporate communication. RNS is the most appropriate fallback for general, non-specific regulatory/investor announcements.
2016-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.